

## Change of Company Secretary

In accordance with ASX Listing Rule 3.16.1, PainChek® Ltd (ASX: PCK) (“PainChek®” or “the Company”) wishes to announce the appointment of Ms. Natalie Climo of Boardroom Pty Limited as Company Secretary, with effect from 19<sup>th</sup> January 2024. For the purposes of ASX Listing Rule 12.6, Ms. Climo will also be the primary person responsible for communications between the Company and ASX.

Ms. Dadswell of Boardroom Pty Limited has notified the Board of her resignation as Company Secretary with effect from 19<sup>th</sup> January 2024. The Board thanks Ms. Dadswell for her support during her time with the Company.

This release has been authorised for release by the Board of Directors.

**For more information:**

Natalie Climo  
Company Secretary, PainChek  
[natalie.climo@boardroomlimited.com.au](mailto:natalie.climo@boardroomlimited.com.au)  
02 8016 2875

Philip Daffas  
CEO, PainChek  
[philip.daffas@painchek.com](mailto:philip.daffas@painchek.com)  
0406 537 235

**About PainChek®**

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

Pain often goes unrecognised and under-treated in people with communication difficulties. PainChek Universal is a clinically validated smartphone-based medical device that enables best practice pain assessment for all people, everywhere.

PainChek Universal is a complete point-of-care solution that combines the existing PainChek® App with the Numerical Rating Scale (NRS). This enables best-practice pain management for all residents living with pain in any environment — from those who cannot verbalise pain to those who can, and those who fluctuate between the two.

The PainChek® App uses artificial intelligence and facial recognition to detect pain in those who cannot self-report. This gives a voice to those who cannot verbalise pain, whilst also driving objectivity and consistency in all assessments. For those who can self-report, PainChek Universal also includes access to the Numerical Rating Scale, a well-established standard used to document pain levels amongst these individuals. PainChek Universal also supports pain assessment using both tools at the point of care, for those people whose ability to communicate fluctuates.

PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for infants who have not yet learnt to speak. Both the adult and infants products have received regulatory clearance in numerous markets including Australia, Europe, UK, NZ, Singapore and Canada.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit [www.painchek.com](http://www.painchek.com)